AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 151 min read

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $968 From $972

Goldman Sachs reduced its price target for Regeneron Pharmaceuticals from $972 to $968. The stock is currently trading at $778.36, up 3.35% over five days and 4.88% year-to-date. The adjustment is based on the firm's valuation and earnings per share revisions.

Original reporting
marketscreener.com
Published Oct 15, 2026, 10:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$REGN
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

Analyst target changes can influence short‑term trading sentiment and may lead to modest price adjustments.

02

Market read

The target adjustment is a modest but actionable piece of news for Regeneron shareholders and traders.

03

What to watch

Potential pipeline milestones or upcoming earnings could offset the modest target reduction.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Goldman Sachs issued a new price target for Regeneron, adjusting it down by $4.

Market effects

Sector

May temper optimism for biotech sector peers as analysts reassess valuation multiples.

Regional

Limited to US markets where Regeneron trades; no broader regional effect.

Global

Minimal global impact; primarily affects Regeneron investors.

Counterpoint

What could challenge this read

The target cut could be an overreaction; the stock may still have upside if upcoming data beats expectations.

Key entities

  • analyst
    Goldman Sachs

    Investment bank providing the price target revision.

  • company
    Regeneron Pharmaceuticals

    US‑listed biotech firm (ticker RGEN) subject of the target change.

Read at source← All news

Related articles

OCT 16
$REGNMed

Tricks, treats, and trial results in biotech

A report found 15 biotech companies, including ThermoFisher and MilliporeSigma, manipulated antibody assay images. Regeneron's free gene therapy for hearing loss sparked debate. Novartis faced setbacks with failed trials. FDA introduced fast-track programs for ultra-rare diseases and a PreCheck initiative for drug manufacturing.

bioxconomy.com5 min
OCT 16
$REGNMed

CHMP Backs Less Frequent Regeneron's Libtayo Dosing Across Approved Cancer Indications In Europe

Regeneron (REGN) announced the EMA's CHMP recommended an updated dosing regimen for Libtayo (cemiplimab) across all approved EU indications. The new regimen reduces dosing frequency after 12 weeks. The European Commission will make a final decision in the coming months. Libtayo is approved in over 30 countries for various cancers. REGN stock closed at $769.34, up 2.31%.

rttnews.com2 min
OCT 16
$LLYHigh

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

tradingview.com2 min
OCT 16
$REGNMed

CHMP backs wider dosing gap for Regeneron’s Libtayo

Regeneron Pharmaceuticals (NASDAQ: REGN) announced on 16 October 2026 that the European Medicines Agency's CHMP recommended a less frequent dosing schedule for its cancer drug Libtayo, moving from every three weeks to every six weeks after an initial 12-week period. The change, if approved by the European Commission, would apply across all of Libtayo's approved cancer indications in the EU.

financial-news.co.uk2 min
OCT 16
$REGNMed

EU advisers recommend a 15-minute option for some cancer infusions after a tolerated first dose

Regeneron's Libtayo (cemiplimab) received a positive opinion from the EMA's CHMP for an alternative dosing schedule. The new regimen includes a 700 mg dose every six weeks after an initial 12-week regimen of 350 mg every three weeks, with a potential 15- to 30-minute infusion time for the 350 mg dose. The European Commission is expected to make a final decision in the coming months.

stocktitan.net2 min